Vor Biopharma Inc. (NYSE:VOR) Receives $8.86 Consensus Target Price from Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned an average rating of "Buy" from the seven research firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.86.

A number of brokerages have commented on VOR. Wedbush reiterated an "outperform" rating and issued a $7.00 target price on shares of Vor Biopharma in a report on Thursday, March 20th. Oppenheimer reiterated an "outperform" rating and issued a $8.00 price target on shares of Vor Biopharma in a report on Friday, March 21st. HC Wainwright reduced their price objective on Vor Biopharma from $17.50 to $13.00 and set a "buy" rating for the company in a research note on Friday, March 21st. JMP Securities restated a "market outperform" rating and set a $12.00 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus dropped their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 21st.

Vor Biopharma Price Performance

Shares of NYSE VOR traded down $0.01 during midday trading on Thursday, reaching $0.75. 157,095 shares of the stock traded hands, compared to its average volume of 590,688. The stock has a market capitalization of $51.70 million, a PE ratio of -0.46 and a beta of -0.40. The company's 50 day moving average is $1.16 and its 200 day moving average is $1.01. Vor Biopharma has a one year low of $0.63 and a one year high of $2.43.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VOR. Two Sigma Investments LP grew its position in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares during the last quarter. Northern Trust Corp increased its position in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma in the 4th quarter valued at $102,000. RA Capital Management L.P. lifted its stake in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Vor Biopharma in the 4th quarter worth approximately $80,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.